ReviewCancers2022
De-Escalating the Management of In Situ and Invasive Breast Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Global Trends in Surgical Oncology Deescalation Phase III Randomized Trials.Annals of surgical oncology · 2026Article
- De-Escalation of Axillary Surgery: A Review of Choosing Wisely Guideline Evidence.World journal of oncology · 2026Review
- Radiation Therapy De-escalation in Breast Cancer Patients With Pathologic Complete Response: An Integrated Analysis Using Real-World and Simulated Data.International journal of radiation oncology, biology, physics · 2026Article
- Current pattern of care in radiation therapy for DCIS in Australia and New Zealand - where are we heading?Breast (Edinburgh, Scotland) · 2025Article
- Physical Health Decline After Chemotherapy or Endocrine Therapy in Breast Cancer Survivors.JAMA network open · 2025Article
- Targeting PGK1: A New Frontier in Breast Cancer Therapy Under Hypoxic Conditions.Current issues in molecular biology · 2024Review
- Cryotherapy in the Treatment of Early-Stage Breast Cancer.World journal of oncology · 2024Review
- Percutaneous ultrasound-guided cryoablation for early-stage primary breast cancer: a follow-up study in Japan.Breast cancer (Tokyo, Japan) · 2024Article
- Tools to Guide Radiation Oncologists in the Management of DCIS.Healthcare (Basel, Switzerland) · 2024Review
- AI-Enhanced PET and MR Imaging for Patients with Breast Cancer.PET clinics · 2023Review
- Are the Number of Operations Appropriate to Define a High-Quality Breast Cancer Center?World journal of oncology · 2023Article
- Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.European journal of cancer (Oxford, England : 1990) · 2023Article
- The Evolving Approach to Breast Cancer: Moving toward De-Escalating Treatment and Personalized Medicine.Cancers · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is necessary to identify appropriate areas of de-escalation in breast cancer treatment to minimize morbidity and maximize patients' quality of life. Less radical treatment modalities, or even no treatment, have been reconsidered if they offer the same oncologic outcomes as standard therapies. Identifying which patients benefit from de-escalation requires particular care, as standard therapies will continue to offer adequate cancer outcomes. We provide an overview of the literature on the de-escalation of treatment of ductal carcinoma in situ (DCIS), local treatment of breast cancer, and surgery after neoadjuvant systemic therapy. De-escalation of breast cancer treatment is a key area of investigation that will continue to remain a priority. Improvements in understanding the natural history and biology of breast cancer, imaging modalities, and adjuvant treatments will expand this even further. Future efforts will continue to challenge us to consider the true role of various treatment modalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.